ABP 692

DRUG2 trials

Sponsors

Amgen Inc., Amgen

Conditions

Relapsing-remitting Multiple SclerosisRelapsing-remitting Multiple Sclerosis (RRMS)

Phase 3

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Active, not recruitingNCT06700343

AmgenRelapsing-remitting Multiple Sclerosis (RRMS)

Start: 2025-01-13End: 2027-10-04Updated: 2026-07-27

A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis

RecruitingCTIS2024-512914-16-00

Amgen Inc.Relapsing-remitting Multiple Sclerosis

Start: 2025-09-12Target: 370Updated: 2025-12-01